Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: mannitol; silicon dioxide; copovidone; sodium stearylfumarate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - pharmacor linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,pharmacor linezolid is active against gram-positive bacteria only. pharmacor linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; copovidone; mannitol; silicon dioxide; sodium stearylfumarate; titanium dioxide; hypromellose; macrogol 400 - akm linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,akm linezolid is active against gram-positive bacteria only. akm linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; mannitol; pregelatinised maize starch; silicon dioxide; copovidone; titanium dioxide; hypromellose; macrogol 400 - akm linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,akm linezolid is active against gram-positive bacteria only. akm linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid cip is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid cip is active against gram-positive bacteria only.,linezolid cip has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: maize starch; hyprolose; sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid cip is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid cip is active against gram-positive bacteria only.,linezolid cip has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

United Kingdom - English - myHealthbox

actavis group ptc ehf - linezolid - film-coated tablets - 600mg - other antibacterials - nosocomial pneumonia community acquired pneumonia linezolid is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms). linezolid is not active against infections caused by gram negative pathogens. specific therapy against gram negative organisms must be initiated concomitantly if a gram negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; sodium starch glycollate type a; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - cipla linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,cipla linezolid is active against gram-positive bacteria only. ,cipla linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; sodium starch glycollate type a; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - cipla linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,cipla linezolid is active against gram-positive bacteria only. ,cipla linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - linezolid - film-coated tablet - linezolid 600 mg - antibacterials for systemic use

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - linezolid - film-coated tablet - linezolid 600 mg - antibacterials for systemic use